Kontafarma China Overhauls Board and Committee Structure

Kontafarma China Holdings Ltd ( (HK:1312) ) has provided an announcement.

Kontafarma China Holdings Ltd has reshuffled its board structure with effect from 16 April 2026, confirming Wang Feifei as chairman and president alongside two other executive directors, one non-executive director and three independent non-executive directors. The updated governance framework formalizes responsibilities across seven board committees, concentrating key oversight roles in the hands of committee chairmen who hold casting votes, which may streamline decision-making and strengthen corporate governance oversight for shareholders.

The new committee composition assigns Wang Feifei to chair the executive, nomination, risk management, share dealing and investment committees, while independent directors lead the audit and remuneration committees. This configuration underscores a balance between executive leadership and independent scrutiny, signaling the company’s effort to reinforce governance discipline, risk control and accountability to investors within its Hong Kong-listed corporate structure.

More about Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd is a Cayman Islands-incorporated company listed in Hong Kong. The group operates through a board structure comprising executive, non-executive and independent non-executive directors, supported by multiple specialist committees overseeing audit, remuneration, nomination, risk management, share dealing and investment matters.

Average Trading Volume: 1,458,687

Technical Sentiment Signal: Sell

Current Market Cap: HK$167.4M

For an in-depth examination of 1312 stock, go to TipRanks’ Overview page.